CRO Ltd. initiated a Phase I clinical trial of GBPD060, BANGAVAX in healthy human volunteers. Sponsor of the clinical trial was Globe Biotech Ltd. Bangladesh. The study was discontinued by the sponsor as the COVID-19 pandemic came to an end.
Clinical Research Organization
crobangladesh@gmail.com
+8801819251514
Phase I Clinical Trial of mRNA-based SARSCoV-2 vaccine in humans
A clinical trial to evaluate the immunogenicity and SARSCoV-2 neutralization in Rhesus macaque (Macaca mulatta) after immunization with GBPD060, BANGAVAX was conducted by CRO Ltd. successfully.
Sponsor of the clinical trial was Globe Biotech Ltd. Bangladesh. It was monitored by Directorate General of Drug Administration, Bangladesh, Bangabandhu Sheikh Mujib Medical University, Dhaka and Bangladesh Medical Research Council.
The clinical trial found GBPD060, BANGAVAX to safe and effective in Rhesus macaque and paved the way for a Phase I clinical trial of this COVID-19 vaccine candidate in humans.